BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 1321494)

  • 1. Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript.
    Bickmore WA; Oghene K; Little MH; Seawright A; van Heyningen V; Hastie ND
    Science; 1992 Jul; 257(5067):235-7. PubMed ID: 1321494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative splicing and genomic structure of the Wilms tumor gene WT1.
    Haber DA; Sohn RL; Buckler AJ; Pelletier J; Call KM; Housman DE
    Proc Natl Acad Sci U S A; 1991 Nov; 88(21):9618-22. PubMed ID: 1658787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.
    Wang ZY; Qiu QQ; Huang J; Gurrieri M; Deuel TF
    Oncogene; 1995 Feb; 10(3):415-22. PubMed ID: 7845666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA recognition by splicing variants of the Wilms' tumor suppressor, WT1.
    Drummond IA; Rupprecht HD; Rohwer-Nutter P; Lopez-Guisa JM; Madden SL; Rauscher FJ; Sukhatme VP
    Mol Cell Biol; 1994 Jun; 14(6):3800-9. PubMed ID: 8196623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional repression mediated by the WT1 Wilms tumor gene product.
    Madden SL; Cook DM; Morris JF; Gashler A; Sukhatme VP; Rauscher FJ
    Science; 1991 Sep; 253(5027):1550-3. PubMed ID: 1654597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression in Xenopus oocytes shows that WT1 binds transcripts in vivo, with a central role for zinc finger one.
    Ladomery M; Sommerville J; Woolner S; Slight J; Hastie N
    J Cell Sci; 2003 Apr; 116(Pt 8):1539-49. PubMed ID: 12640038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product.
    Nakagama H; Heinrich G; Pelletier J; Housman DE
    Mol Cell Biol; 1995 Mar; 15(3):1489-98. PubMed ID: 7862142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product.
    Bardeesy N; Pelletier J
    Nucleic Acids Res; 1998 Apr; 26(7):1784-92. PubMed ID: 9512553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Wilms tumor 1 transactivation by bone marrow zinc finger 2, a novel transcriptional repressor.
    Lee TH; Lwu S; Kim J; Pelletier J
    J Biol Chem; 2002 Nov; 277(47):44826-37. PubMed ID: 12239212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant.
    Haber DA; Park S; Maheswaran S; Englert C; Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
    Science; 1993 Dec; 262(5142):2057-9. PubMed ID: 8266105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA binding by the Wilms tumor suppressor zinc finger proteins.
    Caricasole A; Duarte A; Larsson SH; Hastie ND; Little M; Holmes G; Todorov I; Ward A
    Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7562-6. PubMed ID: 8755514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAX 8 regulates human WT1 transcription through a novel DNA binding site.
    Fraizer GC; Shimamura R; Zhang X; Saunders GF
    J Biol Chem; 1997 Dec; 272(49):30678-87. PubMed ID: 9388203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers.
    Little MH; Holmes G; Pell L; Caricasole A; Duarte A; Law M; Ward A; Wainwright B
    Oncogene; 1996 Oct; 13(7):1461-9. PubMed ID: 8875984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of the remaining allele of the WT1 gene in a Wilms' tumour from a WAGR patient.
    Brown KW; Watson JE; Poirier V; Mott MG; Berry PJ; Maitland NJ
    Oncogene; 1992 Apr; 7(4):763-8. PubMed ID: 1314370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
    Park S; Tomlinson G; Nisen P; Haber DA
    Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the cellular protein encoded by the human Wilms' tumor (WT1) gene.
    Telerman A; Dodemont H; Degraef C; Galand P; Bauwens S; Van Oostveldt P; Amson RB
    Oncogene; 1992 Dec; 7(12):2545-8. PubMed ID: 1334252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of Wilms tumor WT1 splice variants on the insulin receptor promoter.
    Webster NJ; Kong Y; Sharma P; Haas M; Sukumar S; Seely BL
    Biochem Mol Med; 1997 Dec; 62(2):139-50. PubMed ID: 9441865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor.
    Rauscher FJ
    FASEB J; 1993 Jul; 7(10):896-903. PubMed ID: 8393820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of RNA aptamer binding by the Wilms' tumor suppressor protein WT1.
    Zhai G; Iskandar M; Barilla K; Romaniuk PJ
    Biochemistry; 2001 Feb; 40(7):2032-40. PubMed ID: 11329270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.